In Part 1, we introduced SMB acquisition investing as an emerging, cash-flow-driven, private asset class that offers a risk-return profile distinct from early-stage venture capital, making it a potentially attractive tool for portfolio diversification. Now, we turn to the practical process of evaluating these opportunities.
- Clinical Trial Confirms GammaTile Superior Tumor Control
- 2025 Brutal Biotech Investment Climate
- Delta Development Team – Introducing BloodCOMM Premium
- Special Operations Forces Blood Cooler from Delta Development
- UACI startup alumni Reglagene making impressive strides in brain cancer treatment
- Reglagene RGN6024 Cover Story August 2025 Molecular Cancer Therapeutics
- Calls for More Angel Investing
- Takes a Licking and Keeps on Ticking
- Ventura County firefighters make history with in-the-field blood transfusions
- FireRescue1’s “3 Things We’re Watching at FDIC 2025